Tagged with INVIMA

LatAm From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already considered global standards. According to the Waiting to Access Innovative Therapies (W.A.I.T.) Indicator from FIFARMA, an association representing research-based pharma…

LatAm Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and routine immunisation disrupted by pandemic aftershocks, even long-protected regions are witnessing a resurgence in preventable diseases. In Latin America, where…

Colombia Francisco Rossi, Director of Colombia’s National Food and Drug Surveillance Institute (INVIMA), discusses the agency’s ongoing transformation to become a faster, more transparent, and globally recognised regulator. Since his return in 2024, Rossi has prioritised reducing backlogs, launching the digital platform InvimÁgil, and refocusing INVIMA on public health surveillance. He…

LatAm A roundup of some of the latest stories from Latin American pharma and healthcare, including Sanfer’s acquisition of Columbia-based injectables manufacturer Vitalis; medicine shortages in Colombia, and Chile’s move towards universal primary health coverage with support from the World Bank.   ACON Investments Signs Definitive Agreement to Sell Vitalis to…

Colombia Luz Stella Gomez, General Manager for the Colombian medical device distributor Gemedco, talks about the positive impact that INVIMA’s regulations have had on the Colombian health sector, Gemedco’s portfolio evolution since General Electric’s acquisition, upcoming partnerships for 2017 and the company’s focus on bringing value to the market. Ms. Gomez,…

Colombia In explaining the role of the Colombia National Food and Drug Surveillance Institute (INVIMA) and its impact on the regulatory landscape of the healthcare sector, Javier Guzman, Executive Director, centres the discussion on four key pillars: institutional strengthening, efficiency, transparency and competitiveness. He speaks about his main priorities, the Colombian…